"Drug closing in on Alzheimer's"
Source: The Australian
Published: 20 Sep 2008
Category: Pharmaceutical
Rating:
(4½ stars)
what they said (Hover the mouse cursor over underlined words for more info)
BETA-amyloid protein isn't really much to look at. A tangle of amino acids, for much of our lives it exists harmlessly in our brains.
The original article can be found at: http://www.theaustralian.news.com.au/story/0,25197,24368210-23289,00.html
| Criteria |
Rating |
| Novelty of Treatment |
Satisfactory (?) |
| Availability of Treatment |
Satisfactory (?) |
| Treatment Options |
Satisfactory (?) |
| Disease Mongering |
Satisfactory (?) |
| Evidence |
Satisfactory (?) |
| Quantification of Benefits of Treatment |
Not Satisfactory (?) |
| Harms of Treatment |
Satisfactory (?) |
| Costs of Treatment |
Not Applicable |
| Sources of Information |
Satisfactory (?) |
| Relies on Press Release |
Satisfactory (?) |
what we said (Hover the mouse cursor over underlined words for more info)
This is more of a feature article than news. It covers in some detail the development and early human testing of a drug that is designed to deplete amyloid-â peptide Aâ42, thought by some to be a cause of Alzheimer's disease. Strong features of the article are that it goes well beyond the media release that accompanied publication of the clinical trial report in July 2008 and the cautionary note that these are very early clinical data. The article could have pointed out that this was a randomised placebo controlled trial of two doses of the experimental drug. It could also have mentioned that rates of diarrhoea and nausea were slightly higher with the experimental drug than with placebo. But overall this is good reporting containing much of what we'd like to see in health reports
public forum
There are currently no comments on this article.
|